Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study.

Ariotti, Sara; Ortega-Paz, Luis; van Leeuwen, Maarten; Brugaletta, Salvatore; Leonardi, Sergio; Akkerhuis, K Martijn; Rimoldi, Stefano F; Janssens, Gladys; Gianni, Umberto; van den Berge, Jan C; Karagiannis, Alexios; Windecker, Stephan; Valgimigli, Marco; Investigators, HI-TECH (2018). Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study. JACC. Cardiovascular Interventions, 11(16), pp. 1576-1586. Elsevier 10.1016/j.jcin.2018.04.022

[img] Text
Ariotti JACCCardiovascInterv 2018.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy


The study sought to assess whether treatment with ticagrelor, as compared with prasugrel and clopidogrel, improves endothelium-dependent dilation throughout the course of the treatment and other vascular biomarkers, including systemic adenosine plasma levels.


The in vivo off-target effects of ticagrelor in post-acute coronary syndrome (ACS) patients remain poorly characterized.


Fifty-four stable post-ACS patients were sequentially exposed to each of the 3 oral P2Y inhibitors following a 3-period balanced Latin square crossover design with 4 weeks per treatment in 5 European centers. The primary endpoint was the assessment of endothelial function with pulse amplitude tonometry and expressed as reactive hyperemia index at treatment steady state. Secondary endpoints included reactive hyperemia index after loading or before maintenance regimen, systemic adenosine plasma levels, a wide set of vascular biomarkers, and ticagrelor or AR-C124910XX plasma levels throughout each ticagrelor period. In 9 patients, the evaluation of endothelial function was performed simultaneously by pulse amplitude tonometry and flow-mediated dilation.


Reactive hyperemia index did not differ after ticagrelor (1.970 ± 0.535) as compared with prasugrel (2.007 ± 0.640; p = 0.557) or clopidogrel (2.072 ± 0.646; p = 0.685), nor did systemic adenosine plasma levels or vascular biomarkers at any time points. P2Y platelet reactivity units were lower after ticagrelor as compared with clopidogrel at all time points and after maintenance dose as compared with prasugrel. Flow-mediated dilatation did not differ after the maintenance dose of ticagrelor as compared with clopidogrel and prasugrel.


Ticagrelor did not improve endothelial function or increased systemic adenosine plasma levels as compared with prasugrel and clopidogrel in stabilized patients who suffered from an ACS. (Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans [HI-TECH]; NCT02587260).

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine (ISPM)
04 Faculty of Medicine > Pre-clinic Human Medicine > CTU Bern

UniBE Contributor:

Ariotti, Sara; Rimoldi, Stefano; Karagiannis Voules, Alexios; Windecker, Stephan and Valgimigli, Marco


600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services








Tanya Karrer

Date Deposited:

31 May 2018 12:02

Last Modified:

04 Nov 2019 20:50

Publisher DOI:


PubMed ID:


Additional Information:

Autor für Post-Print angefragt. 31.5.2018/tka

Uncontrolled Keywords:

P2Y(12) inhibitors adenosine endothelial function prasugrel ticagrelor





Actions (login required)

Edit item Edit item
Provide Feedback